UroGen Pharma Ltd (NASDAQ: URGN) is -22.77% lower on its value in year-to-date trading and has touched a low of $3.42 and a high of $18.15 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The URGN stock was last observed hovering at around $13.02 in the last trading session, with the day’s gains setting it 2899986.98%.
Currently trading at $2900000.0, the stock is 14.13% and 35.56% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.84 million and changing -0.46% at the moment leaves the stock 18.69% off its SMA200. URGN registered 21.69% gain for a year compared to 6-month loss of 20.45%. The firm has a 50-day simple moving average (SMA 50) of $9.5602 and a 200-day simple moving average (SMA200) of $10.9188.
The stock witnessed a 167.77% gain in the last 1 month and extending the period to 3 months gives it a 21.92%, and is -5.54% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.11% over the week and 15.76% over the month.
UroGen Pharma Ltd (URGN) has around 235 employees, a market worth around $597.55M and $91.87M in sales. Profit margin for the company is -150.68%. Distance from 52-week low is 278.95% and -28.60% from its 52-week high. The company has generated returns on investments over the last 12 months (-176.37%).
The EPS is expected to grow by 1.54% this year
191.0 institutions hold shares in UroGen Pharma Ltd (URGN), with institutional investors hold 113.10% of the company’s shares. The shares outstanding are 46.10M, and float is at 39.62M with Short Float at 15.46%. Institutions hold 105.33% of the Float.
The top institutional shareholder in the company is RTW INVESTMENTS, LP with over 3.56 million shares valued at $59.69 million. The investor’s holdings represent 9.661 of the URGN Shares outstanding. As of 2024-06-30, the second largest holder is ADAGE CAPITAL PARTNERS GP, L.L.C. with 3.3 million shares valued at $55.37 million to account for 8.9621 of the shares outstanding. The other top investors are RA CAPITAL MANAGEMENT, L.P. which holds 3.08 million shares representing 8.3739 and valued at over $51.74 million, while GREAT POINT PARTNERS LLC holds 7.8927 of the shares totaling 2.91 million with a market value of $48.77 million.
UroGen Pharma Ltd (URGN) Insider Activity
The most recent transaction is an insider sale by Schoenberg Mark, the company’s Chief Medical Officer. SEC filings show that Schoenberg Mark sold 5,162 shares of the company’s common stock on Jun 09 ’25 at a price of $7.37 per share for a total of $38044.0. Following the sale, the insider now owns 0.15 million shares.
Still, SEC filings show that on Jan 31 ’25, Schoenberg Mark (Chief Medical Officer) disposed off 4,551 shares at an average price of $11.14 for $50698.0. The insider now directly holds 145,666 shares of UroGen Pharma Ltd (URGN).
